The randomized ALLIANCE A051701 trial closed early when treatment-related toxicity and mortality were increased without improving PFS in patients with newly diagnosed double-hit lymphoma.
|Articles|December 7, 2021
Daily Medication Pearl: Asparaginase (Rylaze)
Author(s)Saro Arakelians, PharmD
Rylaze is a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma.
Advertisement
Medication Pearl of the Day: Asparaginase (Rylaze)
Indication: Rylaze is an asparagine-specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients.
Insight:
- Dosing: When replacing a long-acting asparaginase product, the recommended dosage of Rylaze is 25 mg/m2 administered intramuscularly every 48 hours.
- Dosage forms: Injection 10 mg/0.5 mL solution in a single-dose vial.
- Adverse events (AEs): The most common AEs (incidence > 20%) are abnormal liver test, nausea, musculoskeletal pain, fatigue, infection, headache, pyrexia, drug hypersensitivity, febrile neutropenia, decreased appetite, stomatitis, bleeding, and hyperglycemia.
- Mechanism of action: Asparaginase (recombinant)-rywn is an enzyme that catalyzes the conversion of the amino acid L-asparagine into aspartic acid and ammonia. The pharmacological effect is based on the killing of leukemic cells due to depletion of plasma asparagine.
- Manufacturer: Jazz Pharma
Sources:
Advertisement
Related to this article
Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.
Thomas Hope, MD, explains why radioligand therapies should be evaluated according to whether their clinical benefits outweigh their risks within the context of patients’ available cancer treatment options.
Robin Tumlinson, PharmD, BCOP, discusses how rapidly expanding bladder cancer options are creating new questions around treatment sequencing, toxicity management, biomarker testing, and multidisciplinary care.
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.
Helicobacter pylori exposure could be associated with approximately 22% of colorectal cancer cases worldwide.
Eight-year phase 3 ADAURA trial data show adjuvant osimertinib boosts survival in patients with resected EGFR-mutant NSCLC.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
3
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
4
Baseline Interferon Activity in Monocytes Predicts mRNA Vaccine Adverse Effects, Study Finds
5